Vol.

No.

February 12, 2021Feb 12, 2021

DOWNLOAD THE PDF

Cover Story

NCI raises paylines, commemorates 50th anniversary of the National Cancer Act of 1971

By Alexandria Carolan and Matthew Bin Han Ong

Pandemic notwithstanding, NCI is on track to reach the 15th percentile for the payline by 2025—a goal set by institute Director Ned Sharpless in response to a deluge of grant applications.

Black History Month Conversation with The Cancer Letter

VCU's Rob Winn reflects on a year of COVID, racial reckoning, and being the sole Black director of an NCI-designated cancer center

By Paul Goldberg

Come back later: ODAC rejects accelerated approval of neoadjuvant Keytruda in TNBC

By Paul Goldberg

COVID-19 & Cancer

Uğur Şahin: Pfizer-BioNTech mRNA coronavirus vaccine is “fastest vaccine developed and approved in medical history”

By Matthew Bin Han Ong

COVID-19 & Cancer

Peter Marks: How FDA crunched COVID-19 vaccine review timelines without compromising safety or efficacy

By Alexandria Carolan

In Brief

Anne Chiang named deputy chief medical officer and chief integration officer at Smilow Cancer Hospital

Sachin Apte named chief clinical officer of Huntsman Cancer Institute

Alan Tackett named deputy director of UAMS Winthrop P. Rockefeller Cancer Institute

Sybil R. Green named first diversity and inclusion officer of ASCO

Patrick Delaney named executive director of NCCN Foundation

City of Hope receives $100M donation from Arthur Riggs

MSK receives $7M donation, establishes newly endowed chair and fellowships for health equity and diversity

Yale Cancer Center and Smilow Cancer Hospital receives $750,000 grant to address cancer health inequality

Biden's former Cancer Moonshot Blue Ribbon panel members, oncology leaders pen letter supporting Janet Woodcock for FDA commissioner

Funding Opportunities

DOD ovarian cancer research funding opportunity for FY21

DOD lung cancer research funding opportunity for FY21

Clinical Roundup

ASCO, Friends of Cancer Research recommend broadening eligibility criteria in cancer clinical trials

CRISPR tech targets human genome's complex code

Drugs & Targets

Ukoniq receives FDA accelerated approval for marginal zone lymphoma and follicular lymphoma

Breyanzi receives FDA approval for adults with relapsed or refractory large-B-cell lymphoma

Libtayo receives FDA approval as first immunotherapy for patients with advanced basal cell carcinoma

MD Anderson, Mirati Therapeutics collaborate on KRAS and solid tumor research

Inrebic received European Commission approval for myelofibrosis

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 50 | Issue 46 - December 13, 2024